New stock news | Tangji Medical plans to list on the Hong Kong stock market. The China Securities Regulatory Commission requires additional clarification on the compliance of the implemented stock incentive plan, etc.

On May 22nd, the China Securities Regulatory Commission announced the requirements for supplementary materials for overseas issuance and listing filing (from May 18th, 2026 to May 22nd, 2026). The International Department of the China Securities Regulatory Commission issued supplementary material requirements for 17 companies, including requesting Tangji Medical to provide supplementary explanations on the compliance of the implemented equity incentive plan. It is reported that Tangji Medical submitted an application to the Hong Kong Stock Exchange on February 9th, 2026, with Guotai Junan International and CICC International as its joint sponsors. The China Securities Regulatory Commission requested Tangji Medical to provide explanations on the following matters and requested lawyers to verify and provide clear legal opinions: 1. Please supplement the specific compliance with overseas investments, forex management and other regulatory procedures of your company's overseas subsidiaries, and provide conclusive opinions on compliance. 2. Please supplement the information on the development and operation of websites, apps, mini-programs, etc., by your company, the scale of user information collected and stored, data collection and usage, whether it involves providing personal user information to third parties, arrangements or measures for personal information protection and data security before and after listing. 3. Please supplement the reasons for the reasonableness of the prices of new shareholders entering the company in the last 12 months, the differences in the prices of such shareholdings, and provide a clear conclusion on the existence of benefits transfer, etc. 4. Please supplement the compliance of the equity incentive plan implemented by your company, including the composition of specific personnel and their positions, the existence of relationships between participating personnel and other shareholders, directors, supervisors, and senior management of the issuer, fairness of prices, agreement terms, decision-making procedures, regulatory compliance, and provide clear conclusions on legality, compliance, and existence of benefits transfer. 5. Please supplement whether there are any defects such as shares being pledged, frozen, or other rights issues for the shareholders participating in the upcoming "full circulation". The prospectus disclosed that Tangji Medical is a Chinese medical device company focused on providing innovative solutions for the treatment and management of metabolic diseases. The company strategically constructs a product pipeline covering obesity and metabolic disease treatment devices and adapter devices, and full-cycle management products, all of which focus on the treatment and management of metabolic diseases, with indications including overweight, obesity, MASH with obesity and type 2 diabetes with obesity. The company's core product, GBS, is a pioneering MICROPORT device inspired by the weight loss and metabolic benefits of Roux-en-Y gastric bypass surgery (RYGB) for the treatment of obesity. In January 2024, it was approved by the National Medical Products Administration as a Class III Innovative Medical Management device, becoming the first medical device approved for endoscopic treatment of obesity in China.